大眾交通(600611.SH):利鵬行同意出資10880萬元認繳嘉興睿惠的基金份額
格隆匯 10 月 14日丨大眾交通(600611.SH)公佈,2020年10月,大眾交通全資子公司利鵬行與深圳前海簽署了《合夥協議》,利鵬行同意出資人民幣10880萬元認繳嘉興睿惠的基金份額,成為嘉興睿惠的有限合夥人。此次投資資金為利鵬行自有資金。
此次交易完成後,嘉興睿惠的認繳出資總額為人民幣11080萬元;其中,利鵬行將作為有限合夥人持有嘉興睿惠98.19%的份額。
此次投資有助於進一步落實公司發展戰略,藉助專業投資機構的專業優勢參與股權投資項目,提升公司的投資能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.